Esketamine with preparation and integration therapy for treatment-resistant depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-site, randomized, controlled trial in San Juan, Puerto Rico comparing two approaches for adults with treatment-resistant depression who receive FDA‑approved intranasal esketamine twice weekly. All participants receive standard clinical dosing and monitoring; half are randomly assigned to brief, manualized preparation and integration sessions delivered by a trained clinician while the other half receive standard care without those extra sessions. The integration sessions are informed by psychedelic-assisted therapy frameworks and aim to improve safety, emotional processing, and meaning‑making around the esketamine experience. The primary outcome is change in depression severity on the MADRS, with secondary measures including emotional regulation, therapeutic alliance, treatment acceptability, and dissociative experiences.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: Adults aged 21 to 65 years.
* Diagnosis: Current Major Depressive Disorder (MDD) as confirmed by Structured Clinical Interview for DSM5 (SCID-5).
* Treatment Resistance: Failure to achieve remission with at least two antidepressants of adequate dose and duration (TRD criteria) as confirmed by SCID-5.
* Symptom Severity: Baseline Montgomery-Åsberg Depression Rating Scale (MADRS) ≥30.
* Suicidal Ideation: Participants with baseline passive or active suicidal ideation may be included, provided they do not meet criteria for inpatient admission and are deemed clinically stable for outpatient care. This will be measured with the Columbia Suicide Severity Rating Scale (C-SSRS).
* Consent: Ability to understand and voluntarily provide written informed consent.
* Contraception: For participants of reproductive potential, willingness to use at least one highly effective method of contraception (e.g., intrauterine device, hormonal contraception, sterilization) or two effective methods (e.g., barrier method plus spermicide) during the study and for at least one month after the final esketamine dose. Contraceptive method(s) will be documented at baseline via self-report on a standardized form and reaffirmed at each esketamine session by research staff. Participants who become pregnant or are unable to confirm adequate contraception will be withdrawn from the study for safety reasons.
* Availability: Willingness and ability to attend all scheduled sessions and complete study procedures.
* Motivation for Engagement: Demonstrates willingness and psychological readiness to engage in guided reflective work before and after esketamine dosing (as assessed during clinical intake).

Exclusion Criteria:

* Acute Suicide Risk: Immediate need for inpatient psychiatric hospitalization due to suicidal ideation with plan or intent as identified through the C-SSRS.
* Psychotic or Bipolar Disorders: Current diagnosis of bipolar I disorder (manic phase), schizophrenia, schizoaffective disorder, or other primary psychotic disorders if stated by participants as a past diagnosis or identified during the SCID-5.
* Substance Use Disorder: Active moderate to severe substance use disorder (except nicotine) in the past 6 months as self-identified by participant or during the SCID-5.
* Cognitive/Developmental Impairments: Intellectual disability, dementia, or other cognitive/developmental disorders that impair ability to engage meaningfully in structured psychotherapeutic sessions such as preparation or integration, per clinician judgment.
* Medical Contraindications: Any medical condition judged to pose undue risk during esketamine administration (e.g., aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage, or hypersensitivity to esketamine/ketamine).
* Pregnancy/Breastfeeding: Current pregnancy or breastfeeding.
* Ongoing Structured Psychotherapy Likely to Confound Outcomes: Participation in any formal psychotherapy within the past 3 months that involves structured, weekly sessions focused on behavioral change or emotional processing (e.g., CBT, ACT, psychodynamic therapy), unless the therapy was completed or stabilized at a low-intensity level for at least 8 weeks prior to enrollment.
* Prior Non-Response to Esketamine: Six or more prior esketamine (≥56 mg) or IV ketamine sessions (0.4-0.7 mg/kg) without clinical response.
* Recent Ketamine Use: Use of ketamine/esketamine in the past 12 weeks.
* Inability to Consent: Any condition rendering the participant unable to provide informed consent.
* Prior Enrollment: Previous participation in this study.

Where it's running

• Pravan Foundation
  San Juan, Puerto Rico Recruiting
• University of Puerto Rico, Department of Psychiatry
  San Juan, Puerto Rico Recruiting

Study contacts

• Study coordinator: Paulina D Rullan-Farinacci, MD
• Email: paulina.rullan@upr.edu
• Phone: 787-414-3571

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls

  This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.

  Recruiting at 10 sites Fondation FondaMental · Besançon and 16 other locations · NCT07881016

• DHEA add-on to standard antidepressants for treatment-resistant depression

  This trial tests whether adding 100 mg/day of DHEA to patients’ current antidepressant treatment helps people with treatment-resistant depression feel better.

  Recruiting at 9 sites Phase 3 Charite University, Berlin, Germany · Berlin, State of Berlin and 8 other locations · NCT07843927

• One-Day cTBS Over the Precuneus and iTBS Over the Left PFC for Treatment-Resistant Depression

  This study tests whether a one-day accelerated TMS session targeting the precuneus or the left dorsolateral prefrontal cortex can reduce depressive symptoms in adults with treatment-resistant depression, compared with sham stimulation.

  Recruiting Mclean Hospital · Belmont, Massachusetts · NCT07758010

• Predicting Treatment Response in Psychiatric Disorders Using Biological Markers

  This study tests whether biological markers can predict which patients with psychiatric conditions will respond to treatment.

  Recruiting Centre Hospitalier St Anne · Paris · NCT07741981

• Cannabidiol Oil as an Add-on for Treatment-Resistant Major Depression

  This study tests whether full-spectrum CBD oil added to standard antidepressants can help adults with treatment-resistant major depression.

  Recruiting Phase 1/2 Universidade do Sul de Santa Catarina · Tubarão, Santa Catarina · NCT07696871

• Biomarker-guided antidepressant choice to see if rTMS or ketamine works best for you

  This study tests whether brain and behavior markers can help match people with major depression to either rTMS or ketamine to see which works better for them.

  Recruiting at 2 sites Phase 4 Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT07680140

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.